Trump Administration’s Drug Pricing Deals Offer Limited Relief, Analysts Say
A new wave of agreements between the White House and pharmaceutical companies is expected to have a minimal impact on industry profits while primarily offering a reprieve from potential tariffs, according to Wall Street analysis.
On Friday, President Trump announced deals with nine additional drug manufacturers, asserting they would substantially reduce the cost of prescription medications. However, experts suggest the actual impact will be far less significant than portrayed.
The agreements involve individual deals for discounts on specific drugs, many of which were already subject to substantial rebates or were nearing the end of their patent exclusivity. In exchange, these companies will receive a three-year exemption from the Trump administration’s previously threatened tariffs.
Limited Impact on Net Prices
According to a report from William Blair, the deals represent “another round of pandering on carefully selected drugs.” While discounted cash prices will be offered, one analyst noted that the net price reduction is unlikely to be substantial. “The cash prices will likely be well above typical co-pays, meaning people with insurance will buy drugs the same way as in the past,” the analyst explained.
Gilead Sciences, one of the companies involved in the negotiations, anticipates a “manageable” financial impact from the agreement, extending into 2026 and beyond. This sentiment is expected to be consistent across all nine deals, with analysts predicting “no significant impacts on the companies’ growth prospects.”
Investor Confidence Remains High
Despite the ongoing negotiations, investor confidence in the pharmaceutical and biotechnology sectors remains strong. Pharma and biotech indexes have generally risen throughout the year, recovering from a dip in April when the administration initially threatened “major” tariffs. While those threats prompted announcements of increased investment in U.S. manufacturing, the subsequent tariff exemptions significantly lessened their potential impact.
Push for ‘Most-Favored-Nation’ Pricing
The latest agreements are part of the Trump administration’s broader effort to implement “most-favored-nation,” or MFN, pricing for pharmaceuticals. This strategy aims to align U.S. drug costs with those found in countries that utilize price controls. In July, the administration sent letters to 17 major drugmakers, demanding price reductions within 60 days or facing potential government intervention.
Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, and EMD Serono previously reached agreements with the White House. The recent deals include Gilead, Merck & Co., Amgen, Bristol Myers Squibb, GSK, Novartis, Sanofi, Genentech, and Boehringer Ingelheim. Johnson & Johnson, AbbVie, and Regeneron remain as the final three companies expected to reach agreements.
Enforcement Concerns and Additional Incentives
Beyond specific drug pricing, the White House claims the agreements will prevent foreign nations from “free riding on American innovation” by guaranteeing MFN prices for all new medicines developed by the nine companies. However, the method of enforcing this provision remains unclear. Bristol Myers Squibb stated its deal exempts it from “future pricing mandates.”
The agreements also appear to include additional incentives, such as the Food and Drug Administration (FDA) announcing national priority vouchers for expedited reviews of two experimental drugs from Merck on the same day the deals were announced. “
Calls for Transparency
The lack of transparency surrounding the negotiations has drawn criticism from Democratic lawmakers. Four leading members of Congress sent letters to AstraZeneca, Lilly, Novo Nordisk, and Pfizer last week requesting detailed information about the agreements. “Skepticism and scrutiny are warranted as the Trump Administration has repeatedly made announcements that fail to meet their stated goals and instead only increase costs on the consumer,” the lawmakers stated.
